HMGCR and plasma cell myeloma: As shown in Figure 2A, human myeloma and AL amyloid cells were treated with increasing concentrations of lovastatin, an HMG-CoA reductase inhibitor, or digeranyl bisphosphonate (DGBP), a GGDPS inhibitor for 48 hrs.